In accordance with previous results suggesting the favorable role of anti-CTLA-4 antibodies in supporting gemcitabine-based suppression of tumor growth in mice (with anti-CTLA-4 alone exhibiting a slight hampering effect) [17], we found that CTLA-4 blockage effectively supports the response of immune cells against cancer cells. Here, CTLA4 is linked to cancer.